VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study-Reference-Cited by-同舟云学术

VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study

Published:2020-01-30 Issue: Volume:9 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Smyth Elizabeth,Knödler Maren,Giraut Anne,Mauer Murielle,Nilsson Magnus,Van Grieken Nicole,Wagner Anna Dorothea,Moehler Markus,Lordick Florian

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference29 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin.,2018

2. Capecitabine and oxaliplatin for advanced esophagogastric cancer;Cunningham;N Engl J Med,2008

3. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial;Lordick;Lancet Oncol,2013

4. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial;Al-Batran;Lancet.,2019

5. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Smyth;Ann Oncol,2016

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapeutic strategies in gastroesophageal tumors;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

2. Improving individualised therapies in localised gastro-oesophageal adenocarcinoma;The Lancet Oncology;2024-09

3. The current status of immunotherapy and future horizon in the treatment of metastatic and locally advanced gastroesophageal adenocarcinoma;Expert Opinion on Biological Therapy;2024-08-28

4. Prognostic significance of microsatellite instability in patients with resectable gastric cancer;Journal of Gastrointestinal Surgery;2024-08

5. Advances in diagnosis and management of cancer of the esophagus;BMJ;2024-06-03